Bridging the gap in the fight against tuberculosis

Area of Science:

• Microbiology
• Pharmacology
• Drug Development

Background:

• Current preclinical models for tuberculosis (TB) drug discovery do not adequately mimic host conditions or persistent Mycobacterium tuberculosis.
• Effective identification of new anti-TB drugs requires improved preclinical testing systems.

Purpose of the Study:

• To highlight the need for advanced preclinical testing systems for tuberculosis drug development.
• To propose a model-based approach for integrating diverse new technologies in anti-TB drug discovery.

Main Methods:

• Review and synthesis of current challenges in preclinical tuberculosis drug testing.
• Conceptual framework for integrating diverse technological data using a model-based approach.

Main Results:

• Preclinical models must better reflect the diseased host environment and persistent Mycobacterium tuberculosis characteristics.
• A model-based approach can integrate information from novel technologies.

Conclusions:

• Improved preclinical testing systems are essential for identifying effective new tuberculosis drugs.
• Integrating diverse data through a model-based strategy can enhance the successful clinical translation of novel anti-TB compounds.